<DOC>
	<DOCNO>NCT00433745</DOCNO>
	<brief_summary>This study determine safety effectiveness experimental vaccine control abnormal growth cell patient myelodysplastic syndrome ( MDS , also know myelodysplasia ) , acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , chronic myeloid leukemia ( CML ) . It test whether vaccine increase number immune cell respond cancer thereby slow progression illness , improve blood count , reduce need transfusion blood platelet , even achieve disease remission . The vaccine contain part protein produce large amount cell patient cancer add substance call Montanide help immune system respond vaccine . Sargramostim , another substance boost immune response , also give . Patients 18 85 year age MDS , AML , ALL CML may eligible study . Candidates screen medical history , physical examination , blood test , chest x-ray bone marrow biopsy . Women childbearing age also pregnancy test . Participants undergo following : - Chemotherapy enter study . - Leukapheresis collect large amount white blood cell infusion vaccine administration . - Participants may need placement central line ( plastic tube , catheter ) upper part chest use give chemotherapy , blood platelet transfusion , antibiotic white blood cell , collect blood sample . - Weekly vaccine injection nine week , give upper arm , upper leg abdomen . - Sargramostim injection follow vaccination . - Standard care treatment MDS , AML , ALL CML , may include blood platelet transfusion , growth factor , drug control underlie disease potential side effect vaccine . - Weekly safety monitoring , include vital sign check , brief health assessment , blood test observation vaccination , day vaccination . - Follow-up evaluation blood test chest x-ray 3 week last vaccine dose blood test bone marrow biopsy 7 week last vaccine dose .</brief_summary>
	<brief_title>Wilm 's Tumor 1 ( WT1 ) Peptide Vaccine High Risk Hematologic Malignancy</brief_title>
	<detailed_description>Leukemias related disorder myelodysplastic syndrome myeloproliferative disease represent wide group bone marrow stem cell malignancy . Some patient cure chemotherapy allogeneic stem cell transplantation . However , standard treatment approach effective patient become refractory chemotherapy , relapse transplantation progressive disease . The management patient remain unsatisfactory require new treatment approach chemotherapy . The immunological graft-versus-leukemia ( GVL ) effect see allogeneic stem cell transplantation suggest stimulate patient 's T cell responses hematological malignancy might also retard disease progression even achieve disease remission . Wilm 's Tumor 1 ( WT1 ) identify target vaccine antigen antigen over-expressed cluster differentiation 34 ( CD34 ) plus stem cell patient myeloid lymphoid malignancy normal marrow cell . A human leukocyte antigen ( HLA-A0201 ) restrict peptide derive Wilm 's Tumor ( WT ) protein anticipate induce T cell response MDS leukemic cell spar normal cell . Of note , 40 % population HLA-A0201 positive . Therefore propose Phase II trial , second series plan peptide vaccine research , evaluate safety associate immunotherapy approach lymphodepletion , lymphocyte infusion , WT1 vaccination select patient diagnose MDS , AML , ALL CML . The WT1 vaccination comprise 9 dose WT-1 peptide vaccine ( Montanide adjuvant ) administer concomitantly granulocyte macrophage- colony stimulate factor ( GM-CSF ) ( Sargramostim ) . The primary objective evaluate efficacy toxicity associate immunotherapy approach lymphodepletion , lymphocyte infusion , WT1 vaccination select patient hematological malignancy . Secondary objective include evaluation disease response follow number WT1 express cell blood , hematological measurement ( reduction marrow blast cell , change blood count ) , transfusion dependence , time disease progression survival . The primary endpoint side effect treatment ( toxicity number circulate WT1 specific T cell ( efficacy ) measure week 16 study ( 7 week last dose vaccine ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Diagnosed refractory anemia excess blast ( MDSRAEB ) . refractory anemia excess blast transformation ( MDSRAEBt ) . secondary acute myelogenous leukemia ( AML ) . relapse refractory acute chronic myelogenous leukemia ( AML ) . relapse refractory chronic myelogenous leukemia ( CML ) accelerate phase blast crisis relapse refractory acute lymphoblastic leukemia ( high risk ALL ) . acute lymphoblastic leukemia ( ALL ) complete remission . chronic myelomonocytic leukemia ( CMML ) . 2 . Unsuitable stem cell transplantation ( age sixty unavailability fullymatched donor ) . make informed decision undergo transplant procedure . relapse AML , CML , MDS ALL post stem cell transplantation ( SCT ) . 3 . HLAA0201 positive . 4 . Ages 18 85 year . 5 . Off lymphoablative chemotherapeutic agent . 6 . All subject ( men woman ) must agree practice abstinence effective contraception study period . Inclusion Criteria Donor ( post transplant subject without available donor lymphocyte infusion ( DLI ) cell ) : 1 . Related donor , HLA identical ( 6/6 ) recipient . 2 . Age great equal 18 less equal 80 year old . 3 . Ability comprehend investigational nature study provide inform consent . EXCLUSION CRITERIA : 1 . HIV positive ( HIVinfected patient immunecompromised unlikely patient capable mount immune response vaccine ) . 2 . Treatment systemic corticosteroid within 7 day prior study entry . 3 . Low bone marrow reserve ( less 20 percent cellularity ) . 4 . Serum creatinine great 2.5mg/dl serum bilirubin great 4mg/dl ( patient receive fludarabine ) . 5 . Comorbidity severity would preclude patient 's ability tolerate protocol therapy . 6 . Predicted survival le 3 month . 7 . Previous allergic reaction Montanide Adjuvant . 8 . Pregnant breast feeding ( Pregnant breastfeed woman exclude study effect vaccination know may pose risk develop fetus . All female patient urine pregnancy test , test negative allow study ) . 9 . Enrolled another vaccine clinical trial study period . 10 . Inability comprehend investigational nature study provide inform consent . Exclusion CriteriaDonor ( follow ) : 1 . Pregnant lactating . 2 . Unfit receive filgrastim ( GCSF ) undergo apheresis ( abnormal blood count , history stroke , uncontrolled hypertension ) . 3 . HIV positive . 4 . Severe psychiatric illness . Mental deficiency sufficiently severe make compliance bone marrow transplant ( BMT ) treatment unlikely make informed consent impossible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Myelodysplastic Syndrome ( MDS )</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>Chronic Myelogenous Leukemia ( CML )</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Wilm 's Tumor-1 Peptide</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
</DOC>